Search results for "Migraine"
Oral drugs for acute migraines compared head to head
A meta-analysis found that triptans are the most effective medication class for migraine; of individual drugs, eletriptan and ibuprofen provide the most sustained pain relief and are more efficacious than the recently approved drugs lasmiditan, rimegepant, and ubrogepant.
https://immattersacp.org/weekly/archives/2024/09/24/1.htm
24 Sep 2024
Approvals for COVID-19 vaccines, epinephrine nasal spray
This column reviews recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2024/10/approvals-for-covid-19-vaccines-epinephrine-nasal-spray.htm
1 Oct 2024
Prophylactic injectable monoclonal antibody reduced migraine days, industry trial finds
Compared with nonspecific oral drugs, patients treated with erenumab were six times more likely to achieve 50% or more reduction in monthly migraine days and were 11 times more likely to complete the treatment on the first attempt, authors reported.
https://immattersacp.org/weekly/archives/2024/04/02/4.htm
2 Apr 2024
MKSAP Quiz: 2-year history of migraine
A 20-year-old man is evaluated for a 2-year history of migraine that began when he started college. Migraine episodes occur 6 to 12 days per month, with more frequent episodes associated with increased stress from difficult assignments or final examinations. All physical examination findings, including vital signs, are unremarkable. What is the most appropriate preventive measure?
https://immattersacp.org/weekly/archives/2024/03/12/3.htm
12 Mar 2024
New 'weighs' to treat obesity
Even as the data on weight loss drugs mount, physicians need to help patients navigate potentially prohibitive costs and a continuing need for lifestyle change.
https://immattersacp.org/archives/2024/03/new-weighs-to-treat-obesity.htm
1 Mar 2024
Migraine studies find new drug, several existing options all effective for acute treatment
An industry-funded trial found that migraine pain resolved sooner with eptinezumab than placebo, while a meta-analysis found that several established and newer therapies for the acute treatment of migraine were associated with reductions in short-term pain.
https://immattersacp.org/weekly/archives/2021/06/22/5.htm
22 Jun 2021
Talking about migraines
Collecting good data is the first step in sorting through the many drugs and devices that are used to treat migraines.
https://immattersacp.org/archives/2019/07/talking-about-migraines.htm
1 Jul 2019
Ubrogepant appears effective for early acute treatment of migraine
An industry-funded trial found that ubrogepant was associated with absence of moderate or severe headache within 24 hours 46% of the time versus 29% with placebo when taken during the prodrome period (nonaura symptoms preceding headache onset).
https://immattersacp.org/weekly/archives/2023/11/21/2.htm
21 Nov 2023
Set expectations for new migraine treatments
New drugs take aim at migraine prevention, but long-term effects are uncertain.
https://immattersacp.org/archives/2018/10/set-expectations-for-new-migraine-treatments.htm
1 Oct 2018
Erenumab reduced migraines in patients who didn't respond to other treatments, industry-funded study found
An industry-funded study found improvements in primary and secondary endpoints related to migraines with the drug compared to placebo, with similar safety and tolerability.
https://immattersacp.org/weekly/archives/2018/10/30/4.htm
30 Oct 2018